Citadel Advisors’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Citadel Advisors’s Portfolio EFTRW Stock Details EFTRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27,743	Closed	-$3.58K	–	15460
2023 Q1	$3.58K	Buy	27,743 +6,710	+32%	+$1.07K	﹤0.01%	14027
2022 Q4	$3.44K	Buy	+21,033	New	+$2.93K	﹤0.01%	14216
2021 Q3	–	Sell	-200,629	Closed	-$201K	–	14875
2021 Q2	$201K	Buy	200,629 +120,571	+151%	+$97.5K	﹤0.01%	12155
2021 Q1	$48K	Buy	+80,058	New	+$77.3K	﹤0.01%	12923

Other funds holding EFTRW

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.82% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

ICM

III Capital Management Boca Raton, Florida $344M AUM 11.22% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return

SOA

Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Citadel Advisors's EFTRW Position: Q2 2023 in Review

Citadel Advisors sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q2 2023, closing a stake of 27,743 shares — an estimated $3.58K sold.

Citadel Advisors first reported a position in EFTRW in Q1 2021 and held it in 4 quarters. The position peaked at $201K in Q2 2021. 11 funds tracked by Wall St. Rank hold EFTRW as of Q2 2023.

Citadel Advisors reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 27,743 eFFECTOR Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $3.58K.
Citadel Advisors first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 4 quarters.
Citadel Advisors's eFFECTOR Therapeutics, Inc. Warrant position peaked at $201K in Q2 2021.
11 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.